Logo Image
|Articles|January 13, 2023

This Week's Most-Read Infectious Disease Stories

Author(s)Nina Cosdon

It's Friday the 13th, but you can counteract bad luck by catching up on this week's top infectious disease news.

From RSV to hepatitis to avian influenza, this week's most-clicked infectious disease topics remained as varied as ever.

1. On the Precipice of the World's First RSV Vaccine: What's Taking so Long?

RSV cases spiked to unprecedented levels this season. Why were these infections so frequent and severe? Why has vaccine development taken so long?

2. HIVMA Creates Paxlovid Clinical Resources for Treating People With HIV and Hepatitis C

They developed clinical guidance and other resources looking to address potential drug interactions with these patient populations who have COVID-19 and may be treated with Paxlovid.

3. NIH Awards Grants Toward Diagnosis of COVID-19-Related Inflammatory Syndrome in Children

Research will focus on new technologies for early diagnosis of severe illnesses resulting from SARS-CoV-2 infection.

4. Hong Kong Confirms Human Case of Avian Flu, as Colorado Reports Mass Bird Deaths

Hong Kong confirmed a case of a man critically ill with avian influenza. On the other side of the world, Colorado is reporting its worst-ever avian flu outbreak among poultry, migratory birds, and birds of prey.

5. COVID-19 Vaccinations Increased 5.2% This Year. Where Are They Still Lagging?

Good news: across 23 countries, trust in COVID-19 vaccines increased 5.2% from 2021 to 2022. However, vaccine hesitancy remains in key populations.

Related to this article

View more
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Read more
Ceftriaxone Safety: Separating Signal From Risk
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Read more
Treatment of Latent Tuberculosis in a Trice
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Read more
Drawing Borders Around a Borderless Specialty
Drawing Borders Around a Borderless Specialty
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
Read more
Beyond Approval: Finding the Right Place for Emerging Gram-Negative Antibiotics
Beyond Approval: Finding the Right Place for Emerging Gram-Negative Antibiotics
The expanding gram-negative antibiotic pipeline offers important new treatment options; however, FDA approval alone does not define a drug’s place in therapy. Clinicians must weigh the clinical problems that each agent solves, the strength of the evidence behind it, and what remains unknown before incorporating these therapies into routine practice.
Read more